Atazanavir is an antiviral agent, active against HIV infection. It belongs to protease inhibitors. Atazanavir is used in combination with other antiretroviral drugs in patients previously treated with antiretroviral.

Adult Dose
Dose: 300 mg
Single Dose: 300 (300)
Frequency: 24 hourly
Route: PO
Instructions: Adults over 18 years, should be taken with 100 mg Ritonavir and food.
It belongs to Protease Inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Atazanavir is 704.90. It is strongly acidic drug.
Atazanavir is contraindicated in conditions like Diabetes mellitus,Hypersensitivity.
The symptomatic adverse reactions produced by Atazanavir are more or less tolerable and if they become severe, they can be treated symptomatically, these include Alopecia, Diarrhea, Anxiety, Dyspnea, Palpitation, Jaundice, Mouth ulcers, Depression, Arthralgia, Peripheral neuropathy, Syncope, Increased appetite, Chest pain, Urinary frequency, Hypertension, Nephrolithiasis, Amnesia, Proteinuria, Abnormal dreams, Weight changes.
Atazanavir is primarily indicated in conditions like HIV infection in combination with other antiretroviral drugs.
Atazanavir is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbacavirCyclosporin AAtazanavir possibly increases plasma concentration of Cyclosporin.DolutegravirDolutegravir AUC increased 62%; Cmin: increased 121%no dose adjustment requiredErlotinibThis CYP3A4 inhibitor increases levels/toxicity of erlotinibLacosamidePantoprazolePantoprazole may decrease the effectiveness of Atazanavir.RabeprazoleCo-administration of atazanavir with Rabeprazole is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.Concomitant use of atazanavir and Rabeprazole is not recommended.SalmeterolConcurrent use may potentiate the risk of cardiovascular adverse events.SimvastatinAtazanavir inhibits the hepatic metabolism of simvastatin results in increased plasma concentration.MajorThis combination is considered contraindicated. Patient should notify to physician if experience unexplained muscle pain, tenderness, or weakness, malaise or fever. Discontinue therapy if level of creatinine kinase is increased or if myopathy diagnosed.SunitinibMay increases sunitinib concentrations.Tenofovir DisoproxilAtazanavir has been shown to increase tenofovir concentrations.ModerateVemurafenibAtazanavir inhibits P-gp, glucuronidation and CYP3A4, and increases plasma concentration of Vemurafenib.VORICONAZOLEVoriconazole may increase the serum concentration of atazanavir by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Drug Form Store in a well closed container, at room temperature. Protect from Moisture and Heat.
Concomitant use with drugs that prolong PR interval; cardiac conduction disorders. Protease inhibitors are associated with hyperglycaemia and should be used with caution in diabetes. Caution is also needed in patients with haemophilia who may be at increased risk of bleeding. Protease inhibitors should be used with caution in hepatic impairment; the risk of hepatic side-effects is increased in patients with chronuc hepatitis B or C. Atazanavir and fosamprenavir may be used at usual doses in patients with renal impairment. Protease inhibitors should also be used with caution in pregnancy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.